MiniMed 780G system performance in older users with type 1 diabetes: Real‐world evidence and the case for stricter glycaemic targets
This real-world analysis demonstrated that older MiniMed™ 780G system users with type 1 diabetes can achieve a TIR >70% without increasing hypoglycaemia risk. Users employing optimal settings showed the best outcomes. The system performed as well as or better than in younger users. These findings support the case that more stringent TIR targets can be achieved safely.
Authors
- Ohad Cohen (ORCID: https://orcid.org/0000-0003-4337-1795)
- Javier Castañeda (ORCID: https://orcid.org/0000-0003-0752-8847)
- Isabeau Thijs (ORCID: https://orcid.org/0000-0001-5516-4481)
- Simon Heller (ORCID: https://orcid.org/0000-0002-2425-9565)
- David Norman O'Neal (ORCID: https://orcid.org/0000-0002-0870-4032)
- Tali Cukierman‐Yaffe (ORCID: https://orcid.org/0000-0003-1289-5633)
- Arcelia Arrieta (ORCID: https://orcid.org/0009-0003-1684-0258)
- Tim R. A. van den Heuvel (ORCID: https://orcid.org/0000-0002-3907-6876)
- JOHAN H. JENDLE (ORCID: https://orcid.org/0000-0003-1025-1682)
- Vittorino Smaniotto
Institutions
- Tel Aviv University (IL)
- The University of Melbourne (AU)
- Örebro University (SE)
- Sheba Medical Center (IL)
- St Vincent's Hospital Melbourne (AU)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- Medtronic (Switzerland) (CH)
- University of Sheffield (GB)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1111/dom.16227
- Citations
- 10
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 12.95